David Roth - Dec 6, 2023 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Chief Medical Officer
Signature
/s/ Todd Rosenthal, as attorney-in-fact
Stock symbol
SYRS
Transactions as of
Dec 6, 2023
Transactions value $
-$24,834
Form type
4
Date filed
12/8/2023, 04:23 PM
Previous filing
Nov 2, 2023
Next filing
Dec 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYRS Common Stock Sale -$24.8K -6.29K -50% $3.95 6.29K Dec 6, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 was effected pursuant to a trading plan adopted on March 27, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.